Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study

Purpose: To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic toxicities, supportive care requirements, time to complete intensive therapy, and event-free survival (EFS) and overall survival (OS) in children with high-risk acute lymphoblastic leukemia (HR-ALL). Patients and Methods: A total of 287 children with HR-ALL were randomly assigned to intensive chemotherapy regimens (New York I [NY I] or NY II) as part of the Children’s Cancer Group (CCG)-1901 protocol. The induction phases consisted of five drugs (vincristine, prednisone, l-asparaginase, daunorubicin, and cyclophosphamide). Initial consolidation comprised six-agent chemotherapy combined with 18 Gy of total-brain irradiation. Patients were randomly assigned to receive G-CSF (5 μg/kg/day) during either induction or initial consolidation. A crossover study analysis was done on the 259 patients who completed both phases of therapy. Results: The mean time to neutrophil recovery (≥ 0.5 × 109/L) was reduced with G...

[1]  C. R. Pinkerton,et al.  A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. , 2002, Medical and pediatric oncology.

[2]  H. Kantarjian,et al.  Comparison of two different schedules of granulocyte–colony‐stimulating factor during treatment for acute lymphocytic leukemia with a hyper‐CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen , 2002, Cancer.

[3]  T. Salmi,et al.  Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. , 2000, Medical and pediatric oncology.

[4]  A. Baruchel,et al.  Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Amylon,et al.  Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. , 2000, Medical and pediatric oncology.

[6]  F. Dunstan,et al.  Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. , 1999, Medical and pediatric oncology.

[7]  Edward J. Lee,et al.  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.

[8]  H. Sather,et al.  Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features , 1998, Cancer.

[9]  J. Shuster,et al.  Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  U. Jaeger,et al.  Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study. , 1997, Blood.

[11]  M. Stevens,et al.  Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Schrappe,et al.  A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. , 1996, Blood.

[13]  R. Ragusa,et al.  Assessment of the value of treatment with granulocyte colony‐stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial , 1995, European journal of haematology.

[14]  T. Lipp,et al.  Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. , 1995, Blood.

[15]  G. Heller,et al.  Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol , 1993, Cancer.

[16]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Denis R. Miller,et al.  Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure , 1991, Cancer.

[18]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.